Atraverse Medical, a San Diego-based medical device company, has recently achieved two significant milestones in commercializing its leading left-heart access technology. The company’s HOTWIRE radiofrequency (RF) guidewire has been cleared by the FDA, and its seed round was oversubscribed, raising $12.5 million in funding.
The funding includes contributions from prominent physicians, venture investors, and successful entrepreneurs in the medtech industry. This financial support will accelerate the company’s research and development efforts as well as its early commercialization initiatives.
The HOTWIRE system, developed by Atraverse Co-Founders Dr. Steven Mickelsen and Eric Sauter, signifies a new approach to left-heart access. With its universal sheath compatibility and optimized RF technology, the HOTWIRE aims to enhance patient outcomes and streamline procedural workflows.
Dr. Mickelsen emphasized the importance of the FDA clearance for the HOTWIRE in advancing medical innovation and improving procedures requiring transseptal access. Dr. Devi Nair expressed excitement about the impactful changes the HOTWIRE can bring to left-heart therapies. Atraverse Medical CEO/President John Slump highlighted these achievements as positioning them for success in revolutionizing left-heart access technology.
These milestones represent a significant advancement in commercializing Atraverse Medical’s leading left-heart access technology. The funding includes contributions from prominent physicians, venture investors, and successful entrepreneurs in the medtech industry.
The HOTWIRE system signifies a new approach to left-heart access with its universal sheath compatibility and optimized RF technology.
The FDA clearance of the HOTWIRE radiofrequency (RF) guidewire is a major milestone that will enhance patient outcomes and streamline procedural workflows.
Dr. Devi Nair expressed excitement about the impactful changes that Atraverse Medical’s leading left-heart access technology can bring to cardiac electrophysiology procedures.
Atraverse Medical CEO/President John Slump emphasized that these achievements position them for success in revolutionizing left-heart access technology while accelerating their research and development efforts.
